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Infectious disease models play a key role in public health planning.
These models rely on accurate estimates of key transmission
parameters such as the force of infection (FoI), which is the percapita risk of a susceptible person being infected. The FoI captures
the fundamental dynamics of transmission and is crucial for gauging
control efforts, such as identifying vaccination targets. Dengue virus
(DENV) is a mosquito-borne, multiserotype pathogen that currently
infects ∼390 million people a year. Existing estimates of the DENV
FoI are inaccurate because they rely on the unrealistic assumption
that risk is constant over time. Dengue models are thus unreliable
for designing vaccine deployment strategies. Here, we present to
our knowledge the first time-varying (daily), serotype-specific estimates of DENV FoIs using a spline-based fitting procedure designed
to examine a 12-y, longitudinal DENV serological dataset from
Iquitos, Peru (11,703 individuals, 38,416 samples, and 22,301 serotypespecific DENV infections from 1999 to 2010). The yearly DENV FoI
varied markedly across time and serotypes (0–0.33), as did daily
basic reproductive numbers (0.49–4.72). During specific time periods,
the FoI fluctuations correlated across serotypes, indicating that different DENV serotypes shared common transmission drivers. The
marked variation in transmission intensity that we detected indicates that intervention targets based on one-time estimates of
the FoI could underestimate the level of effort needed to prevent
disease. Our description of dengue virus transmission dynamics is
unprecedented in detail, providing a basis for understanding the
persistence of this rapidly emerging pathogen and improving
disease prevention programs.
disease ecology

is a pressing need for accurate, serotype-specific estimates of the
FoI and pc for DENV. Here, we use a unique, long-term serological dataset from Iquitos, Peru to provide to our knowledge
the first such estimates.
Basic mathematical models of pathogen transmission, such as
the catalytic model where the FoI was initially introduced (1),
make simplifying assumptions about the parameters governing
transmission, including the frequent assumption that parameters
do not vary through time in epidemiologically important ways
(10). The assumption that the FoI is constant in time is, however,
inconsistent with current understanding of DENV epidemiology
because transmission clearly varies seasonally and year to year
(8, 11–14). Resolving the magnitude of temporal variations in
the quantities that govern or summarize transmission requires
(i) adequate, temporally resolved incidence data and (ii) development of an estimation approach specifically designed to
use such a dataset to compute time-varying quantities.
Significance
Using mathematical models to extend knowledge of pathogen
transmission and recommend optimized control efforts is dependent on the accuracy of model parameters. The rate at
which susceptible individuals become infected [the force of
infection (FoI)] is one of the most important parameters, but
due to data constraints it is often incorrectly assumed to be
constant over time. Using a bespoke method for a 12-y longitudinal dataset of serotype-specific dengue virus (DENV) infections, we estimated time-varying, serotype-specific FoIs for
all four DENV serotypes. The FoI varied markedly in time, which
implies that DENV transmission dynamics are complex and are
best summarized using time-dependent transmission parameters. Our results provide more accurate measures of virus
transmission dynamics and a basis for improving selection of
control and disease prevention strategies.
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T

he force of infection (FoI) describes the per-capita rate at
which susceptible individuals become infected with a pathogen (1, 2). An accurate estimate of the FoI is essential for parameterizing disease models (3). It can be used to calculate key
quantities such as the basic reproductive number (R0 ) (2, 4) and
the critical vaccination coverage threshold (pc ) of a pathogen (5),
which are frequently used to guide disease control programs and for
determining the control effort required to eliminate a disease (6).
Dengue, a mosquito-borne disease whose incidence and geographic range have increased considerably in the past 50 y (7, 8),
is caused by any of four related but antigenically distinct virus
serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Previous estimates of the FoI for DENV are few and uncertain
owing to limitations inherent to most available DENV datasets,
including difficulty in specifying when an individual DENV infection occurred. Given the growing public health need for optimal vector management strategies and the growing potential
for deployment of a dengue vaccine in the near future (9), there
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Methods
Approval of Experiments Involving Human Subjects. This study used information from participants in five overlapping cohorts. Each had separate
human subjects protocols (see SI Appendix, Table S1 for protocol numbers)
that were in compliance with US federal regulations governing the protections of human subjects. All protocols received approval from the institutional review boards (IRBs) of all participating institutions and from
a Peruvian Ethics Committee that ensured that all Peruvian regulations
governing the protection of human subjects were followed. Starting in 2007,
the Naval Medical Research Center Detachment (now NAMRU-6) formed an
IRB that is registered with the Department of Defense, the Office Human
Research Protection, and the Peruvian Ethics Committee. In addition, all
protocols were reviewed and approved by the Loreto Regional Health Department, which oversees health-related research in Iquitos. In all instances,
written consent was provided by study participants.
Data and Seroconversion Identification. Iquitos is an isolated city of ∼370,000
inhabitants located in the Amazon basin of northeastern Peru. It has been
well described elsewhere (11). All four DENV serotypes have been introduced into Iquitos and subsequently circulated endemically: DENV-1
in 1990 (25), DENV-2 in 1995 (26), DENV-3 in 2001 (11), and DENV-4 in

*Throughout the manuscript, the terms “inapparent” and “clinically apparent” are used
to differentiate between asymptomatic infections or infections with mild symptoms that
do not result in detection through passive case detection (inapparent) and infections
severe enough that the individual seeks medical attention (clinically apparent).
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2008 (27, 28). Our analysis includes 12 y (1999–2010) of data from five
longitudinal dengue cohorts involving Iquitos residents >5 y of age (see
SI Appendix, section S1 and Table S1 for details; Fig. 1). In each cohort,
participants provided blood samples for testing by plaque reduction
neutralization tests (PRNTs) at 6–9 mo intervals. In some circumstances,
studies overlapped in time and space (SI Appendix, section S1). For our
analysis, we combined all cohorts into a single subsample of the Iquitos
population with extensive turnover of individuals throughout the study period. Some of the later cohort studies recruited individuals that were either
not yet born or too young to qualify for inclusion in the first cohort (i.e., aged
less than 5 y in 1999). As such, to maintain a comparable subpopulation (and
avoid confounding effects of birth and a changing population size in Iquitos),
we removed individuals from consideration who were born after 1995. This
resulted in the removal of 1,465 children from consideration. Thus, our
analyses were based on the subpopulation of individuals born before 1995,
which henceforth we will refer to as the sample population.
All blood samples from 1999 through 2010 were analyzed for the presence of
DENV neutralizing antibodies by serotype-specific PRNT (11) in baby hamster
kidney BHK21 cells using a carboxymethyl cellulose overlay. Samples were
considered positive when plaques were reduced 70% or more (PRNT70) using
dilutions of 1:60, 1:80, 1:60, and 1:40 for DENV-1, DENV-2, DENV-3, and DENV4, respectively (11) (SI Appendix, section S2). Chronological sets of PRNT70
results, coupled with knowledge of the timing of DENV serotype introductions
into Iquitos, provided confidence in our interpretation of serologic results (29).
On this basis, we designed an algorithm to identify infections that minimized
the probability of false-positive results by (i) using serotype-specific thresholds,
(ii) ignoring all transient positive results (e.g., negative–postive–negative), and
(iii) eliminating all participants who had any instance of seroconversion to
more than one serotype in the same blood sampling interval (see SI Appendix,
section S2 for details). Completely eliminating such participants from all analyses is quite conservative, but our method of identifying seroconversions relies
on investigating the entire serohistory of an individual. As such, any possibly
erroneous PRNT casts doubt on results for all serotypes. This conservative
approach means our estimates of FoIs are biased low. Our approach
allowed us to identify tertiary and quaternary DENV infections (29) in
part because of sequential introductions of two novel serotypes. Simultaneous virus isolation and identification from dengue cases (i.e., case
data) (30) provided independent validation of the patterns we describe
(Discussion and SI Appendix, section S2).
Model Description. For likelihood-based inference, we estimated the proportion of the study population that had already been infected by time t
[denoted FðtÞ], rather than estimating the FoI directly. Defining λðtÞ as the
FoI at time t, we have (SI Appendix, section S3)

 Zt
λðuÞdu :
FðtÞ = 1 − exp −

[1]

−∞

This equation implicitly assumes that the population is homogeneous and
well mixed (i.e., every individual is equally at risk to be infected by of any
infectious individual). This assumption is imperfect and some of its consequences are discussed below. The data were left-censored (SI Appendix, Fig.
S1A), interval-censored (Fig. 1), and right-censored (SI Appendix, Fig. S1B),
corresponding to individuals who entered the study already seroconverted,
seroconverted between two blood draws, and left the study having never
seroconverted, respectively. Using the probability density function of the
infection times of infected people, f = dF=dt, the likelihood for the three
types of censored data are given in SI Appendix, Table S3 (where I denotes
the time of infection) (31). We considered each individual’s infection status
to be independent of others, which permitted us to take the likelihood of
the data as the product of each individual’s likelihood (SI Appendix,
section S3).
To estimate the FoI through time, we used a nonparametric spline-based
approach (32). Specifically, we defined a set of B-splines (33) as basis functions
for f. The advantages of B-splines over other bases, such as monomials and
trigonometric functions, are that they are flexible and do not a priori assume
periodicity. Based on deviation information criterion (DIC; for details see SI
Appendix, section S5 and Table S2), we identified six B-splines per year (72
total) as the optimal basis for f for the four serotypes and present these
results in the main text. A model using four B-splines per year (48 total) also
worked well (SI Appendix, Table S2, section S6, and Figs. S2–S11). There were
no qualitative differences between results obtained when using a model with
four B-splines per year compared with a model with six B-splines per year.

PNAS | Published online May 20, 2014 | E2695

ECOLOGY

Review of approaches for estimating the FoI of dengue (3)
shows that, mostly owing to data limitations, two approaches have
predominated over the last 30 y (2): (i) methods intended for use
with data collected passively from clinics and hospitals (clinical
cases) and (ii) methods for use with data actively collected from
age-stratified serologic surveys. Data that are collected from
verified clinical cases are temporally resolved but only capture
clinically apparent infections. Not accounting for the potentially
large proportion of undetected, inapparent infections can greatly
diminish the accuracy of FoI estimates (15). Indeed, the ratio of
DENV infections that are subclinical (i.e., inapparent*) to those
that are clinically apparent can be variable and often quite large,
ranging from 0.9:1–40:1 and higher (11, 16–18).
Thus, estimates of the DENV FoI based on verified clinical
cases (e.g., refs. 19–21) are uncertain. In contrast, serological
surveys theoretically capture all (or most) infections in a study
population. The tradeoff is that the actual time of the infection
cannot be defined from a single blood sample, and so the individual’s age is used instead. An important complication for
multistrain pathogens, like DENV, is that the infecting strain is
often not determined in serological surveys. Investigators in
several studies estimated the FoI of DENV using single serological surveys (e.g., refs. 4, 13, and 22), but cross-reactive antibodies obscure identification of the infecting serotype. Thus, in
most dengue endemic settings one cannot resolve potentially
important relationships among serotypes such as antigenicdependent enhancement (23) using single blood specimens from
cross-sectional surveys. Owing to limitations of both serology and
reported clinical case data, current estimates of the FoI for
DENV are uncertain and potentially inaccurate.
Prospective, longitudinal studies generate serial samples from
the same individuals over several years that can be used to validate serological results and derive serotype-specific infection
information (11). A longitudinal study design, therefore, provides data that are amenable to estimating the FoI, particularly if
the FoI changes from year to year and is serotype-specific (24).
Because existing FoI estimation approaches were not designed to
use longitudinal data, we developed a spline-based modeling
approach to analyze a 12-y longitudinal serology dataset (11,703
participants and 38,416 blood samples) from the city of Iquitos,
Peru and produced the first, to our knowledge, time-varying, serotype-specific FoI estimates for DENV.
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Fig. 1. Summary of participants and interval-censored infections. The top panel shows the total number of active participants across cohort studies from
1999 to 2010. The absence of a cohort study from late 2005 to mid-2006 is indicated by the gray shaded region. Remaining panels: After applying the seroconversion identification algorithm to the raw data the number of interval censored infections are plotted against time. For all, the midpoint of the interval
over which the infection was censored is used to time infections.

We could not estimate the function f before 1999 because we did not
have data before that date. Seroconversions that occurred before 1999 were
left-censored, allowing estimation of the proportion of the population that
was exposed before the beginning of the study. We defined κ as the proportion of the population that had seroconverted before 1999:
Zt0
κ =

f ðuÞdu,

[2]

−∞

with t0 representing the beginning of the study. Using Eq. 2, the likelihood
of both right-censored and left-censored observations was rewritten using κ.
Model-Fitting Procedure. To estimate the pdf f, we used a Markov chain Monte
Carlo (MCMC) approach, specifically an adaptive, Metropolis-within-Gibbs algorithm (34, 35) (for complete details on the fitting procedure, see SI Appendix,
section S4 and Figs. S12–S15). We ran 10 chains, each of length 100,000, and
evaluated convergence primarily by monitoring scale reduction factors (SI Appendix, Fig. S13) (36, 37), trace plots (SI Appendix, Fig. S14), and acceptance
probability plots (SI Appendix, Fig. S15). For our analysis, we combined the last
15,000 steps of each chain and randomly sampled 1,000 steps to remove autocorrelation. The parameters were not independent of each other, so to create
credible regions for f (and later the FoI and R0 ) we used the 1,000 sampled steps of

E2696 | www.pnas.org/cgi/doi/10.1073/pnas.1314933111

the chain to create 1,000 estimates of f. This formed an empirical estimate of the
posterior distribution of f. For each day, we then selected the middle 90%
of the estimates to form our Bayesian credible interval (BCI) at that point.
Throughout, in addition to BCIs, we present the posterior medians. There
were two parameters that a priori we knew would have identifiability and
convergence issues: the parameters corresponding to the very beginning
and very end of the study. We, therefore, truncated our estimates to the
region where our chains converged (SI Appendix, section S4 and Figs. S16
and S17). All analyses were done with R (38) and the R package fda (39). We
evaluated convergence with the R package CODA (40).
Parameter and Quantity Estimation. With our estimates of f we computed the
proportion of our study population (those born before 1995) still susceptible
at time t, denoted sðtÞ, as


Zt
f ðuÞdu :
sðtÞ = 1 − κ +

[3]

t0

The FoI, λðtÞ, was then (SI Appendix, section S3)
λðtÞ =

f ðtÞ
:
sðtÞ

[4]

Reiner et al.

[7]

Results
Serotype-Specific Infections. The final dataset included 38,416 blood
samples that provided serotype-specific infection information for
11,703 individuals. Participants provided 1 to 13 (mean = 3.3) sequential samples an average of 249.5 d apart. We identified 22,301
serotype-specific DENV infections, 3,276 of which were intervalcensored (Table 1). Because DENV-1 and DENV-2 had already
circulated in Iquitos for several years before the study began, the
number of left-censored infections for those serotypes was higher
than for DENV-3 and DENV-4. Conversely, the number of interval-censored infections for DENV-3 and DENV-4 was higher,
with DENV-3 accounting for more than half of all interval-censored
infections. Even though DENV-4 was not detected in clinics until
2008, there was still enough transmission for more than 800 individuals that joined the study after 2008 to seem to have already had
neutralizing antibody against DENV-4 (Table 1). Using the mid
date between sample pairs to time when seroconversions occurred,
we found the number of observed infections per month varied
markedly through time (Fig. 1). Testing conducted in 2004 was not
spread out throughout the year and instead occurred at two times.
As such, the mid date of many individuals occurred within same
month (July 2004) which does not necessarily mean that all of these
Table 1. Summary of censored data type by serotype
Data type
Left-censored
Interval-censored
Right-censored

DENV-1

DENV-2

DENV-3

DENV-4

7,714
342
2,527

7,464
408
2,724

2,980
1,701
5,800

867
825
4,658

For each serotype, the number of individuals that were either left-, interval-, or right-censored. Left-censored individuals entered the study already seroconverted to the specific serotype. Interval-censored individuals
became infected to the specific serotype during their time in the study period. Right-censored individuals left the study having never been infected to
the specific serotype. Note that none of the above columns adds up to
11,703 (the total number of participants). For some individuals, no PRNT test
was conclusive for certain serotypes, and as such they were removed from
consideration toward the calculations concerning that serotype. Additionally, DENV-4 was not tested for until 2006, and the smaller number of censored individuals for DENV-4 reflects this.
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Fig. 2. Number and order of interval censored infections by serotype. For
each serotype the number of interval-censored infections are plotted against
year. Note that for comparison purposes the scale of the y axis is not the
same in each panel. Per individual, these infections are broken down by
which infection they constitute (primary, secondary, tertiary, or quaternary).
Because both DENV-1 and DENV-2 cocirculated before the beginning of the
study period, the majority of individuals were already exposed to at least
one of these serotypes and thus most interval-censored infections were not
primary infections. For this same reason (the cocirculation of DENV-1 and
DENV-2 before 1999), there are considerably fewer DENV-1 and DENV-2
interval-censored infections than DENV-3 and DENV-4 interval-censored
infections.

individuals were actually infected in July. Owing to the gap between
cohort studies from late 2005 to mid-2006 (indicated by the shaded
region in Fig. 1), we have no information on infections that occurred during that period (SI Appendix, section S1). In total, 84.0%
of the 11,703 study participants seroconverted to at least one
DENV serotype by the time they left the study. Transmission
varied year to year and across serotypes, with a steady increase
in the number of postsecondary infections (tertiary and quaternary) later in the study (Fig. 2). Overall, the majority of DENV-3
and DENV-4 infections were tertiary or quaternary (65.2% and
77.4%, respectively). For 36.2% of all individuals who seroconverted to DENV-4, it was their fourth infection with a DENV.
Model Parameter Estimates. The proportion of the population
infected before 1999, κ (SI Appendix, Fig. S18), was 55.4% (90%
BCI: 53.8–57%) for DENV-1 (SI Appendix, Fig. S18A) and 52.7%
(90% BCI: 51.5–54%) for DENV-2 (SI Appendix, Fig. S18B).
Conversely, κ was essentially 0 for DENV-3 and DENV-4 [0.004%
(SI Appendix, Fig. S18C) and 0.004% (SI Appendix, Fig. S18D),
respectively], which were introduced later. It is important to
note, however, that DENV-4 was not included in our PRNT
assays until 2006. The fact that these estimates were not exactly
0 was likely an artifact of the fitting procedure because no individuals were identified with a left- or interval-censored DENV-3
or DENV-4 infection until after the respective introductions of
those viruses. Our estimates of the daily probability of infection, f,
showed rough seasonal fluctuations in magnitude across serotypes (SI Appendix, Fig. S19). These estimates were greatest for
DENV-3, particularly in 2002–2003. Over the period of study,
the susceptible proportion of the study subpopulation, sðtÞ
PNAS | Published online May 20, 2014 | E2697
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1
:
R0

1999

R0 was used to calculate the critical vaccination coverage required to eliminate a pathogen. Specifically, the critical vaccination coverage level, pc , satisfies the following relationship (5):
pc ≥1 −

0
100

[6]

Primary
infection

2000

^
RðdÞ
R0 ðdÞ =
:
sP ðdÞ

DENV4

300

We assessed the sensitivity of R0 to this interval in SI Appendix, section S5. We
then used this approximation of the effective reproductive number to calculate
an estimate of the basic reproductive number, R0 , on day d by scaling our approximation by the fraction of the entire population that is susceptible, sP ðdÞ:

DENV3

200

d

100

[5]

500

:
sP ðuÞλðuÞdu

400

3·

300

sP ðuÞλðuÞdu

d+15
Z d+1

DENV2

200

^
RðdÞ ≈ RðdÞ
=

d+18

DENV1
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Z

Approximate number of seroconversions per year

The number of secondary infections caused by a single infectious person at
any time t was the effective reproductive number, denoted RðtÞ. To estimate
RðtÞ for the entire population of Iquitos, we used our FoI estimates to calculate the fraction of the entire population susceptible at any time t,
denoted sP ðtÞ (SI Appendix, section S3). Using the estimated mean time
between successive DENV infections (i.e., serial interval) of 15–17 d (41), we
approximated RðdÞ on day d as the ratio of the number of infections that
occurred between day d and day d + 1 and the average number of infections
15–18 d in the future as follows (SI Appendix, section S3):
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Fig. 3. Daily estimates of FoI. For each serotype, daily estimates of FoI as well as the 90% BCI are plotted against time. The absence of a cohort study from
late 2005 to mid-2006 is indicated by the gray shaded region.

(Methods), decreased for all serotypes (SI Appendix, Fig. S20).
At the end of the study, sðtÞ was reflective of the order of
serotype introductions into Iquitos: DENV-1 (first reported in
1990) = 22.9% (90% BCI: 21.9–23.9%), DENV-2 (first
reported in 1995) = 26.8% (90% BCI: 26.8–28.7%), DENV-3
(first reported in 2001) = 32.0% (90% BCI: 30.9–33.2%), and
DENV-4 (first reported in 2008) = 56.7% (90% BCI: 54.4–
58.6%). Unlike estimates for the sample population, the susceptible
proportion of the entire population of Iquitos, sP ðtÞ, was relatively
stable for DENV-1 and DENV-2 (SI Appendix, Fig. S21). However,
susceptible estimates within Iquitos for the invading serotypes
(DENV-3 and DENV-4) decreased at rates similar to those within
the sample population (SI Appendix, Fig. S21). The estimated age
distribution of infections skewed toward younger individuals the
longer the serotype circulated within Iquitos (SI Appendix, Figs. S22
and S23 and section S5).
FoI. Depending on year and serotype, daily FoI estimates ranged
from 0 to 0.002 (Fig. 3), with the highest estimates being for DENV-3
and DENV-4. Although there was a gap between cohorts from
late 2005 to mid-2006, we did identify nonzero point estimates of
the FoI owing to the slight systematic increase in the proportion of
left-censored individuals that occurred after that period compared
E2698 | www.pnas.org/cgi/doi/10.1073/pnas.1314933111

with before. After analyzing the consistency of estimates across this
gap (SI Appendix, section S5 and Fig. S24), we found that the loss of
data increased median values and credible intervals of estimates
around the gap. Away from the gap, estimated FoI values were
consistent with those in Fig. 3. Further, the large credible intervals
and timing of the estimated peak FoI for 2004 (July 2004) may be
an artifact of the synchronized timing of blood draws in 2004.
Our longitudinal studies captured the introduction of a novel
DENV serotype twice. In late 2001/early 2002, the FoI of the
recently introduced DENV-3 was estimated to be significantly
nonzero, indicating circulation (11). Owing to the regular testing
of the longitudinal cohort participants, the timing of this increase
was distinguishable from that of DENV-1 and DENV-2 (Fig. 3).
This pattern was repeated at the time of the introduction of
DENV-4 in late 2008/early 2009. In both instances, the novel
serotype replaced the existing serotype(s). Weekly and monthly
estimates of the FoI (SI Appendix, Fig. S25 A and B) displayed
similar patterns.
There were periods when transmission of multiple serotypes
seemed to synchronize. We computed Spearman rank correlations
on daily estimates of the FoI between serotypes and found that
DENV-1, DENV-2, and DENV-3 were all highly correlated
(DENV-1/DENV-2: ρ12 = 0:77, DENV-1/DENV-3: ρ13 = 0:54,
Reiner et al.
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Fig. 4. Yearly estimates of FoI. For each serotype yearly estimates of FoI as
well as the 90% BCI are plotted against time. The absence of a cohort study
from late 2005 to mid-2006 does not preclude the estimation of yearly FoI
estimates for either 2005 or 2006, as evidenced by nonzero FoI estimates for
the circulating serotypes for both of those years.

and DENV-2/DENV-3: ρ23 = 0:78). DENV-4, having been introduced in late 2008, does not display high, if any, correlation with
the other serotypes (ρ14 = − 0:068, ρ24 = 0:25, and ρ34 = − 0:037).
FoIs for all serotypes were elevated, however, in late 2009/early
2010, with DENV-1, DENV-2, and DENV-4 reaching their local
maxima at almost the same time in early 2010.
Aggregating our estimates by year indicated that the FoIs for
DENV-3 and DENV-4 were highest (Fig. 4). For both, there
were two years where the yearly FoI exceeded 0.2. The largest
yearly FoI for any serotype was the 2008 estimate for DENV-3
[0.33 (90% BCI: 0.3–0.36)]. Every serotype had at least one
year with a yearly FoI that exceeded 0.1, corresponding to
seroconversion in 10% of members of the study population
that were still susceptible to that serotype in that year. The
FoIs for multiple serotypes were relatively high in 2002, 2004,
2008, and 2010. Conversely, the FoIs of multiple serotypes were
simultaneously relatively low during 2001, 2003, 2005, and 2006
(relative to serotype-specific values for the surrounding years).
The yearly FoIs of DENV-1, DENV-2, and DENV-3 were all
correlated (Spearman rank correlations: DENV-1/DENV-2,
ρ12 = 0:79; DENV-1/DENV-3, ρ13 = 0:73; and DENV-2/DENV-3,
ρ23 = 0:75). Spearman rank correlations with DENV-4 were not
informative because there were only three estimated yearly FoIs
for DENV-4. As noted above with the daily FoI estimates, the
yearly estimates for all four serotypes were high in 2010, each
exceeding 0.1.
Serotype-Specific R0 and Vaccination Thresholds. Our estimates of
RðtÞ and R0 for each serotype fluctuated temporally (SI Appendix, Figs. S26 and S27, respectively). Small variations in the
daily estimates of sP resulted in large variations in R0 because sP
appeared in the denominator of Eq. 6. This resulted in wide
BCIs; the posterior distributions had long upper tails (SI Appendix, Fig. S27). Thus, for the purposes of comparison, we
plotted estimates of R0 with the corresponding 50% BCI (Fig.
5) to truncate extreme values on the upper end of the posterior
distribution. We investigated the sensitivity of these results to
our definition of the serial interval and found that the estimated
values were robust to changes in this interval (SI Appendix,
section S5 and Figs. S28 and S29).
Reiner et al.

Discussion
Our results quantify temporal variation in the FoI for each DENV
serotype over a 12-y period, highlighting marked differences in
transmission intensity both intra- and interannually. We found that
FoI estimates for the recently introduced serotypes DENV-3 and
DENV-4 were higher than those of DENV-1 and DENV-2, which
caused outbreaks before but not during the period investigated
(1990 and 1995, respectively). Overall, there was high correlation
between FoIs across serotypes. There were years of relatively high
(e.g., 2002, 2004, 2008, and 2010) and relatively low (e.g., 2001,
2003, 2005, and 2006) transmission, pointing to common drivers of
DENV transmission dynamics. Our estimates for R0 varied from
∼1 to over 5, depending on year and serotype. During the years
following its invasion, DEN-4 R0 estimates were less than those
for other serotypes. This is consistent with the notion that
DENV-4 is less transmissible than the other three serotypes (42,
43). It should be noted, however, that R0 for DENV-4 appeared
to be increasing as our study period ended. R0 was variable
across seasons, warning against quick estimates for critical
PNAS | Published online May 20, 2014 | E2699
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We did not estimate a value of R0 under 1 for DENV-1 or
DENV-2, except for a small portion of the credible interval in
a few instances. The median values of R0 for DENV-1 ranged
from 1.40 to 3.64. The median values for DENV-2 were lower
(1.36–3.49). Our estimates of DENV-3 ranged from below 1 to
4.72 by 2010. For DENV-4, R0 stayed below 2 until 2010, when it
increased to 3.19 (Fig. 5). Weekly and monthly estimates of R0
(SI Appendix, Fig. S25 C and D) resulted in similar, slightly lower
values. There was a considerable amount of fine-scale temporal
variation in all four R0 estimates. Computing the cross-correlation between the FoI and R0 revealed a systematic lag of ∼60–80 d
(Pearson correlation, SI Appendix, Fig. S30A and Spearman
correlation, SI Appendix, Fig. S30B). Plotting R0 against the FoI
(SI Appendix, Fig. S31) illustrates that sharp increases in the FoI
were preceded by sharp spikes in R0 .
Analogous to the computation of yearly FoI estimates, we
computed yearly average R0 values (SI Appendix, Fig. S32) by
taking the weighted average of the daily R0 estimates (weighted
by relative number of infections). As with the daily R0 estimates,
the yearly estimates for DENV-1 and DENV-2 were relatively
similar, with DENV-1 estimates slightly higher. The yearly R0
estimate of DENV-3 experienced the largest jumps from one
year to the next (2005–2006: 1.38–1.97 and 2008–2009: 1.82–
2.61). Averaging over an entire year ignores seasonality, and the
highest yearly R0 estimates were lower than the highest daily
estimates for all serotypes. For DENV-2 and DENV-3, the
highest yearly R0 estimates occurred in 2010 [DENV-2: 2.54
(50% BCI: 2.45–2.63) and DENV-3: 2.61 (50% BCI: 2.55–
2.69)], and the highest yearly R0 estimate for DENV-1 and
DENV-4 occurred in 2010 [DENV-1: 2.62 (50% BCI: 2.56–
2.68) and DENV-4: 1.43 (50% BCI: 1.39–1.47)].
From serotype to serotype and across years, values of R0 and,
in turn, pc , varied. When DENV-3 or DENV-4 were first introduced (when the entire study population was susceptible), the
estimated R0 was effectively 1 [DENV-3: 50% BCI: (0.80–1.45);
DENV-4: 50% BCI: (0.76, 1.44)], giving pc ≈ 50%. Using the
upper bound on the 90% credible interval for DENV-4 at the
time of its introduction (2.18), we found pc = 54%. In the first 4 y
of the study, the largest median R0 calculated was 3.64 for
DENV-1 in 2001. In the next 4 y, the largest identified was 3.07
for DENV-2 in 2004. In the last 4 y, the largest identified R0 was
4.72 for DENV-3 in 2010. These values result in recommendations
of vaccination coverage of 73, 67, and 79% of the population, respectively. Using the largest yearly R0 estimate (2.61 for DENV-3
in 2009), 62% of the population would need to react to vaccination
with a protective immune response. Conservatively, following the
highest estimated R0 overall (4.72 for DENV-3 in 2010), our results
indicate a vaccine should be distributed to 79% of the population.
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Fig. 5. Daily estimates of R0 . For each serotype daily estimates of R0 as well as the 50% BCI are plotted against time. The absence of a cohort study from late
2005 to mid-2006 is indicated by the gray shaded region. The estimates for both DENV-3 and DENV-4 are truncated, excluding estimation before their respective introductions.

vaccination coverage. Using the highest estimated R0 values (for
DENV-3 from 2010), we conservatively calculated pc to be 79%.
Our yearly DENV FoI estimates mostly fell within the wide
range of previously calculated estimates conducted in a variety of
locations using an array of methods and datasets that often aggregated across DENV serotypes. Yearly FoI estimates ranged
from 0.07– 0.14 (19) to 0.2–0.25 (4, 22) in Thailand to 0–0.3 (13)
in Brazil. Similar to the FoI, our estimates of the R0 of DENV
fell within the wide range of previously published values (1.3–
6.3) (44). As detailed in a review of previous R0 estimation
efforts (44), only three estimation methods used serotype-specific data (4, 19, 45), and only one of those was based on serological surveys (a study using single blood samples from 1,009
children all collected in early 1980) (4). Our estimates indicate
dengue is slightly more transmissible than directly transmitted
diseases such as severe acute respiratory syndrome (R0 ∼ 2‒5)
(46) and influenza (R0 ∼ 2‒3) (47) and less transmissible than fastspreading diseases such as measles and pertussis (R0 ∼ 12‒18 and
∼12–18, respectively) (48). Although our estimated critical
vaccination percentage of 79% was high, it was considerably
lower (and thus vaccination would be a more reasonable control
option) than that for measles and pertussis (∼92–94%).
E2700 | www.pnas.org/cgi/doi/10.1073/pnas.1314933111

Our serotype-specific approach revealed synchronous dynamics among DENV serotypes. There were high correlations in
both the daily and yearly estimates of FoI between DENV-1,
DENV-2, and DENV-3. DENV-1, DENV-2, and DENV-4 all
achieved their local maxima at essentially the same time in 2010.
There were several transmission seasons when, independent of
the size of the serotype-specific susceptible pool, there seemed
to be more than 40 seroconversions to at least three different
serotypes (Fig. 2), specifically in 2004, 2008, and 2010, even
though for at least 2004 surveillance data suggested a single serotype dominated (30). Even under stricter schemes for identification of seroconversions (SI Appendix, section S2 and Fig.
S33), there remained periods where multiple serotypes seemed
to circulate concurrently. This emphasizes the potential for differences between patterns of disease (i.e., clinically apparent
infections) and patterns of infection. A study identifying the
timing of serotype-specific outbreaks of dengue in Thailand (49)
similarly identified seasonal synchronization across serotypes,
specifically between DENV-1, DENV-2, and DENV-3. DENV-4,
however, was reported to be out-of-phase. Our estimated FoIs
for DENV-1, DENV-2, and DENV-4 were at or close to their
highest values at almost the exact same time in 2010, indicating
Reiner et al.
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temporary cross-protection. Following a DENV infection, an individual has temporary immunity to heterologous DENV infection
(57), which may have affected our estimates (44). Correcting for
cross-protection would result in a systematic increase in our FoI
estimates because temporarily immune individuals would be removed from the heterologous susceptible pool in the denominator of
Eq. 4. Likewise, incorporating death would increase our estimates.
Although they require considerable effort, time, and resources, longitudinal studies provide valuable detailed information
on pathogen transmission, especially when rates of asymptomatic
infection are high, like they are for DENV (16). Because most
estimation attempts are not based on longitudinal data, the
methods to use such detail are not well developed. As noted
earlier, the use of likelihood-based fitting of smooth functions for
the FoI has been developed for data from a single serological
survey of individuals within the study population (2). By combining a spline-based approach with equations previously derived
in the field of reliability (31) we developed an estimation method
that incorporates the detailed information provided by a longitudinal study and allows for temporal flexibility in FoI estimates.
Our method was designed to work with a particular dataset but
could be adapted to other longitudinal studies for dengue and
other infectious diseases.
Our analysis and the interpretation of serological data were facilitated by the two novel DENV introductions that took place
during the period of study. In both cases, the novel serotype initially
displaced the preexisting serotypes. After this initial phase, however,
neither of the novel serotypes seemed to interfere with the others. If
Iquitos begins to sustain simultaneous transmission of all four
serotypes, the maintenance of longitudinal cohort studies will provide valuable data for confirming the patterns we identified and/or
reveal further complexity in the interplay among serotypes.
Conclusions
Beyond clear intra-annual, seasonal variation, the observed
temporal variation in epidemiological parameters (especially
from year to year) implies that the transmission dynamics of
DENV in Iquitos are complex and cannot be summarized with
synoptic data or assumptions of time-independent transmission
parameters. In addition to informing dengue prevention strategies, connecting the variation of these estimates to other processes, such as measures of entomological risk (i.e., mosquito
abundance) and climatic variation, will inform local control
strategies. The minimal vaccine coverage required to effectively
control dengue varies by serotype. Given a potentially limited
number of doses, efficiently distributing a vaccine within and
between communities can only be optimized when these variations are understood and taken into account. Because vaccines
may not have perfect efficacy (9), the incorporation of accurate,
serotype-specific estimates of critical transmission parameters
will be crucial for selecting delivery strategies and determining
the optimal mix of vaccination and vector control for sustainable
prevention of dengue.
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that the interserotypic immune reactions that drive patterns of
transmission among serotypes may vary in their influence in different contexts. We also noted that invading serotypes replaced
the existing serotype(s) that had been previously circulating at
relatively high levels. Novel serotype invasions are rare events, in
our case two over 12 y, which prevented us from performing
statistical tests on serotype replacement patterns.
The synchrony between serotypes indicates there are common
drivers. DENV is dependent on a mosquito population to complete
its transmission cycle. Interannual variation in climate drivers can
thus impose variation on transmission dynamics through their influence on mosquito biology and ecology. As in many cities with
endemic dengue, Iquitos employs various mosquito control strategies in response to increases in dengue cases. We are currently
investigating relationships between interannual variation in potential climate drivers, vector control efforts, and FoI estimates.
Although we computed daily estimates of R0 , there was no inherent reason why these estimates should not all be equal. By investigating which assumptions were violated to produce such
temporally fluctuating estimates and, in particular, produce the
lagged patterns observed between our estimates of R0 and the FoI,
it was possible to indirectly deduce characteristics of transmission
dynamics. For instance, the repeating pattern of a sharp spike in R0
followed by a relatively slower increase and then decrease of the
FoI was consistent with violation of the assumption of a well-mixed,
spatially homogeneous population. We considered the Iquitos cohort to be one subpopulation, but in reality people (and their exposure to Aedes aegypti bites in locations other than their home)
were nonhomogeneously distributed across the city (28, 50). These
heterogeneities can have important implications for epidemiological
prediction and inference (51). Localized outbreaks occur in Iquitos
(52), and thus focal outbreaks would best be scaled by focal levels of
human immunity. Perhaps if we incorporated the relatively rapid
depletion of locally susceptible individuals there would be a more
gradual change in the estimated values of R0 . Another spatial
heterogeneity that could contribute to the patterns we observed was
the variation in individual movements. Some people may have
contributed more to transmission than others by moving about
more, being bitten by more mosquitoes, being more infectious, or
some combination of these factors (53). Perhaps once an outbreak
was initiated the pathogen spread to less-transmissible individuals,
decreasing the aggregated R0 estimates.
Certain caveats exist with our approach. First, cross-reacting
anti-DENV antibodies can result in false-positive PRNT results
(54, 55). We compensated for this by excluding individuals who
seemed to seroconvert to multiple serotypes in the same time
period and by using an individual’s entire serohistory to guard
against transient false positives. This does not guarantee that we
completely controlled for incorrectly serotyping an infection
owing to a cross-reaction. Although there were periods of synchrony between the serotypes, increases, for example, in the
number of DENV-3 seroconversions were not systematically
accompanied by an increase in DENV-1 seroconversions. As
such, we concluded that it is unlikely that cross-reacting antibodies, rather than cocirculation of multiple serotypes of DENV,
were responsible for our results. Second, although the virus isolation and PCR data confirm certain patterns (e.g., the timing of
the DENV-3 and DENV-4 invasions), virus detection was not always concordant with the longitudinal serological data. Virus detection in cell culture and PCR indicated that one or at most two
predominant serotypes at a time produced clinically apparent
infections. The patterns of inapparent infections do not by definition exactly match those of apparent infections (15). Considering
the complex interplay between order of infection and severity of
disease, especially for tertiary and quaternary infections (29, 56), it
was not surprising that virus isolation/PCR data and the longitudinal serologic data did not always perfectly agree. Third, we modeled each serotype independently, ignoring the potential effects of
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